Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $1.71.

  • Apellis Pharmaceuticals' EPS (Basic) rose 47173.91% to $1.71 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.35, marking a year-over-year increase of 11732.67%. This contributed to the annual value of -$1.6 for FY2024, which is 6411.2% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' EPS (Basic) is $1.71, which was up 47173.91% from -$0.33 recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' EPS (Basic) peaked at $1.71 during Q3 2025, and registered a low of -$2.72 during Q2 2021.
  • In the last 5 years, Apellis Pharmaceuticals' EPS (Basic) had a median value of -$1.17 in 2023 and averaged -$1.07.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 19527.39% in 2021, then skyrocketed by 47173.91% in 2025.
  • Apellis Pharmaceuticals' EPS (Basic) (Quarter) stood at -$1.53 in 2021, then rose by 1.96% to -$1.5 in 2022, then surged by 52.0% to -$0.72 in 2023, then soared by 59.28% to -$0.29 in 2024, then skyrocketed by 683.22% to $1.71 in 2025.
  • Its EPS (Basic) stands at $1.71 for Q3 2025, versus -$0.33 for Q2 2025 and -$0.74 for Q1 2025.